Observational analysis reveals increased cancer risk with sulfonylureas, glinides, and insulin in type 2 diabetes, highlighting the need for therapeutic safety evaluations.
The results showed that sulfonylureas and glinides increased the risk for overall cancer, but to a lesser extent than insulin. Therapies that are associated with cancer risks certainly require further investigation.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: